IMPAX to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

January 31, 2007

HAYWARD, Calif.--(BUSINESS WIRE)--Jan. 31, 2007--IMPAX Laboratories, Inc. (OTC: IPXL) today announced that management will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on Wednesday, February 7, 2007 at 11:40 a.m. Eastern Time. The conference will be held on February 6-8, 2007 at the Grand Hyatt Hotel in New York City.

Individuals may listen to the live and archived presentation, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. To listen to the live presentation, please go to the web site 15 minutes prior to its start to register, download, and install the necessary audio software. The presentation will be archived on the Company's web site for 14 days.

About IMPAX Laboratories, Inc.

IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. IMPAX markets its generic products through its Global Pharmaceuticals division and markets its branded products through the IMPAX Pharmaceuticals division. Additionally, where strategically appropriate, IMPAX has developed marketing partnerships to fully leverage its technology platform. IMPAX Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com.

CONTACT: Company Contacts:
IMPAX Laboratories, Inc.
Larry Hsu, Ph.D. President & CEO
510-476-2000, Ext. 1111
or
Arthur Koch, CFO,
215-933-0351
www.impaxlabs.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz,
212-838-3777
kgolodetz@lhai.com
or
Bruce Voss,
310-691-7100
bvoss@lhai.com
www.lhai.com

SOURCE: IMPAX Laboratories, Inc.